Your browser is no longer supported. Please, upgrade your browser.
REGN Regeneron Pharmaceuticals, Inc. daily Stock Chart
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E22.69 EPS (ttm)18.46 Insider Own0.90% Shs Outstand105.95M Perf Week2.50%
Market Cap44.38B Forward P/E18.50 EPS next Y22.64 Insider Trans-1.43% Shs Float76.03M Perf Month13.51%
Income2.12B PEG1.83 EPS next Q5.74 Inst Own73.70% Short Float2.61% Perf Quarter4.96%
Sales6.37B P/S6.97 EPS this Y70.80% Inst Trans0.08% Short Ratio2.48 Perf Half Y13.90%
Book/sh72.83 P/B5.75 EPS next Y4.25% ROA18.50% Target Price428.27 Perf Year12.81%
Cash/sh20.69 P/C20.24 EPS next 5Y12.42% ROE25.90% 52W Range281.89 - 420.48 Perf YTD12.14%
Dividend- P/FCF27.26 EPS past 5Y14.30% ROI22.30% 52W High-3.42% Beta1.25
Dividend %- Quick Ratio3.60 Sales past 5Y33.60% Gross Margin93.40% 52W Low44.07% ATR12.02
Employees6200 Current Ratio4.00 Sales Q/Q10.80% Oper. Margin37.00% RSI (14)62.15 Volatility2.50% 3.27%
OptionableYes Debt/Eq0.00 EPS Q/Q55.70% Profit Margin28.20% Rel Volume0.73 Prev Close418.84
ShortableYes LT Debt/Eq0.09 EarningsFeb 06 BMO Payout0.00% Avg Volume800.58K Price406.12
Recom2.50 SMA205.43% SMA509.64% SMA20014.00% Volume340,600 Change-3.04%
Jan-04-19Upgrade Guggenheim Neutral → Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $415
May-04-18Reiterated Canaccord Genuity Hold $356 → $304
Apr-09-18Downgrade Raymond James Outperform → Mkt Perform
Feb-21-18Downgrade Canaccord Genuity Buy → Hold $522 → $356
Jan-09-18Reiterated Citigroup Neutral $380 → $388
Dec-01-17Downgrade Citigroup Buy → Neutral $480 → $380
Nov-09-17Reiterated RBC Capital Mkts Sector Perform $473 → $425
Oct-24-17Resumed Guggenheim Buy $540
Oct-20-17Downgrade Barclays Equal Weight → Underweight $450 → $395
Sep-29-17Resumed Piper Jaffray Overweight $540
Sep-15-17Initiated RBC Capital Mkts Sector Perform $475
Sep-06-17Resumed Raymond James Outperform $566
Aug-17-17Initiated Evercore ISI Outperform $605
Aug-04-17Reiterated UBS Buy $489 → $535
Aug-01-17Downgrade Robert W. Baird Neutral → Underperform $408
Jun-30-17Reiterated BTIG Research Buy $480 → $540
Jun-26-17Downgrade Bernstein Outperform → Mkt Perform
Jun-20-17Reiterated Piper Jaffray Overweight $446 → $557
May-05-17Upgrade Canaccord Genuity Hold → Buy $375 → $484
Jan-20-19 10:15AM  3 Healthcare Stocks Hitting 52-Week Highs: Are They Buys? Motley Fool
Jan-18-19 04:12PM  These 3 Biotech Stocks Appear Poised To Beat Fourth-Quarter Forecasts Investor's Business Daily
04:01PM  Regeneron to Report Fourth Quarter and Full Year 2018 Financial and Operating Results and Host Conference Call and Webcast on February 6, 2019 PR Newswire
09:10AM  Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies Zacks
Jan-17-19 03:04PM  Stock Market Jumps On China Tariff News; Netflix Holds Tight Ahead Of Results Investor's Business Daily
09:06AM  J&J (JNJ) to Commence Pharma Q4 Earnings: What to Expect Zacks
07:40AM  Report: Exploring Fundamental Drivers Behind SkyWest, Pacific Biosciences of California, Lennar, Regeneron Pharmaceuticals, MGM Growth Properties, and Cincinnati Bell New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-16-19 04:55PM  Regeneron (REGN) Sails Steady on Label Expansion of Drugs Zacks
12:08PM  REIT Stocks, Medical Stocks Lead New Buys By The Best Mutual Funds Investor's Business Daily
Jan-15-19 03:04PM  3 of the Top Big Pharma Stocks to Buy Now InvestorPlace
02:26PM  Can Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Maintain Its Strong Returns? Simply Wall St.
11:15AM  How To Trade Growth Stocks: The Easy Way To Check And Confirm Institutional Support Investor's Business Daily
10:19AM  5 Companies Hit 52-Week Highs
10:10AM  Can Regeneron (REGN) Keep the Earnings Surprise Streak Alive? Zacks
Jan-11-19 09:04AM  3 Biotech Stocks Bubbling Away Investopedia
Jan-10-19 12:57PM  Oakmark Funds Bill Nygren Discusses Poor Q4 Performance He Is Not Losing Confidence Insider Monkey
Jan-09-19 01:46PM  Market Leaderships Odd Couple: Wingstop and Regeneron InvestorPlace
09:33AM  Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-08-19 08:56AM  4 Biotechs That Are Potential Buyouts Post Celgene Deal Zacks
Jan-07-19 06:18PM  Regeneron, Sanofi Restructure Immuno-Oncology Collaboration Zacks
02:28PM  U.S. top court rejects Amgen over cholesterol medication patent fight Reuters
02:25PM  U.S. top court rejects Amgen over cholesterol medication patent fight Reuters
12:33PM  Sanofi to pay Regeneron $462 million in revised immuno-oncology deal Reuters
12:21PM  UPDATE 1-Sanofi to pay Regeneron $462 mln in revised immuno-oncology deal Reuters
07:00AM  Regeneron Provides Update on Commercial and Pipeline Progress at J.P. Morgan Healthcare Conference PR Newswire
02:51AM  Drugmakers Sanofi, Regeneron restructure immuno-oncology deal Reuters
02:32AM  Sanofi and Regeneron Restructure Immuno-Oncology Collaboration for Discovery and Development Programs GlobeNewswire
02:30AM  Regeneron and Sanofi Restructure Immuno-Oncology Collaboration for Discovery and Development Programs PR Newswire
Jan-04-19 11:30AM  Regeneron Stock Is the Latest Biotech Bottle Rocket +6.85%
11:08AM  The 3 Best Stocks to Buy At the End of the Bear Market InvestorPlace
Dec-31-18 04:15PM  Does Pfizer Have A Multibillion-Dollar Replacement For Opioids? Investor's Business Daily
Dec-26-18 03:12PM  Value Investors Should Buy into the Teva Stock Dip InvestorPlace +6.65%
Dec-24-18 10:08AM  Health care going negative after starting quarter strong CNBC Videos
Dec-20-18 01:23PM  Regeneron to receive up to $140 million from state toward $800 million expansion American City Business Journals
Dec-19-18 08:03AM  How Should Investors Feel About Regeneron Pharmaceuticals, Inc.s (NASDAQ:REGN) CEO Pay? Simply Wall St.
Dec-18-18 04:01PM  Regeneron Announces Presentation at the 37th Annual J.P. Morgan Healthcare Conference PR Newswire
Dec-17-18 09:08AM  5 Excellent GARP Picks With Cheap PEG Ratio Zacks
Dec-14-18 10:50AM  Global fears strike Wall Street Yahoo Finance
Dec-13-18 06:00AM  Chris Childrose has hired 1,500 employees. Shes only halfway done American City Business Journals
Dec-12-18 03:17AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen Zacks
Dec-11-18 10:26AM  Moderna Stock Ushers In the Next Wave of Biotech InvestorPlace
09:00AM  4 Biotech Stocks Investors Can Add to Their Portfolio in 2019 Zacks
12:59AM  Hedge Funds Are Crazy About Regeneron Pharmaceuticals Inc (REGN) Insider Monkey
Dec-06-18 01:48PM  3 Top Stocks After #ASH18 Motley Fool
Dec-04-18 03:13PM  Eye Drug Continues to Drive Regeneron's Growth
07:00AM  Today's Research Reports on Trending Tickers: Regeneron Pharmaceuticals and Global Blood Therapeutics ACCESSWIRE
Dec-03-18 08:00AM  Detailed Research: Economic Perspectives on TESARO, Regeneron Pharmaceuticals, Pool, Zebra Technologies, Cadence Design, and TherapeuticsMD What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-01-18 12:00PM  Regeneron Presents Positive Data at ASH for REGN1979 CD20xCD3 Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma PR Newswire
12:00PM  Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals Motley Fool
Nov-28-18 05:19PM  Galapagos' Osteoarthritis Candidate Gets Fast Track Status Zacks
Nov-23-18 06:46AM  Why I Like Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Simply Wall St.
Nov-21-18 02:17PM  Pfizer Stock Has Multiple Positive Catalysts InvestorPlace
Nov-20-18 05:00PM  Regeneron Announces Upcoming Investor Conference Presentation PR Newswire
03:52PM  Glaxo Seeks Label Expansion of Nucala in Pediatric Patients Zacks
Nov-18-18 03:00PM  2 Well-Known Stocks to Consider Shorting Thanksgiving Week
Nov-16-18 04:16PM  Regeneron (REGN) Rides on Eylea and Dupixent's Performance Zacks
09:02AM  The Zacks Analyst Blog Highlights: PetroChina, NextEra, Eni, Dr Pepper and Regeneron Zacks
Nov-14-18 04:06PM  This Potential Blockbuster Drug Is Plateauing But Analyst Remains Bullish Investor's Business Daily
09:15AM  Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges Zacks
Nov-11-18 08:15AM  ODYSSEY OUTCOMES investigators highlight at AHA that Praluent® (alirocumab) Injection was associated with fewer deaths from any cause PR Newswire
08:14AM  ODYSSEY OUTCOMES Investigators Highlight at AHA that Praluent® (alirocumab) Injection Was Associated with Fewer Deaths from Any Cause PR Newswire
Nov-09-18 04:32PM  Waiting for bluebird bio to Sing at ASH Motley Fool
Nov-07-18 11:40PM  Edited Transcript of REGN earnings conference call or presentation 6-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
05:07PM  New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) cardiovascular outcomes trial GlobeNewswire
05:01PM  New England Journal of Medicine Publishes Positive Detailed Results From Praluent® (alirocumab) Injection Cardiovascular Outcomes Trial PR Newswire
05:00PM  New England Journal of Medicine publishes positive detailed results from Praluent® (alirocumab) Injection cardiovascular outcomes trial PR Newswire
10:08AM  Sanofi Eczema Drug Dupixent's sBLA Gets Priority Review Zacks
Nov-06-18 04:45PM  Regeneron Crushes Profit Views, But Cuts A Key Piece Of Its Outlook Investor's Business Daily
04:41PM  Regeneron (REGN) Q3 Earnings Beat Estimates, Revenues In Line Zacks
04:05PM  Regeneron Pharmaceuticals Inc (REGN) Q3 2018 Earnings Conference Call Transcript Motley Fool
01:44PM  Will Stocks Gain After the Elections? & Earnings from CVS, LLY, HEAR Zacks
10:39AM  September JOLTS Report In Spotlight Zacks
10:29AM  Playing the Waiting Game; Plus MedTech, Pharma in Q3 Earnings Zacks
10:09AM  Stocks Rally As Voters Go To The Polls; This Top Stock Breaks Out Investor's Business Daily
08:34AM  Regeneron Pharma Earnings, Revenue beat in Q3
08:00AM  FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis PR Newswire
07:50AM  Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates Zacks
07:23AM  Trump's drug price crack down could squeeze Regeneron and Eylea profits American City Business Journals
07:04AM  The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering Benzinga
06:44AM  Regeneron: 3Q Earnings Snapshot Associated Press
06:30AM  Regeneron Reports Third Quarter 2018 Financial and Operating Results PR Newswire
03:50AM  Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA Reuters
01:16AM  Sanofi and Regeneron's Dupixent gets more positive feedback from U.S. FDA - companies Reuters
01:02AM  FDA grants priority review for Dupixent® (dupilumab) as potential treatment for adolescents with uncontrolled moderate-to-severe atopic dermatitis GlobeNewswire
12:59AM  FDA Grants Priority Review for Dupixent® (dupilumab) as Potential Treatment for Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis PR Newswire
Nov-05-18 02:28PM  Biogen Stock Rebounds After Impressive Q3 Earnings InvestorPlace
02:06PM  Hedge Funds Were Overwhelmingly Bullish On This Stock Insider Monkey
01:19PM  Regeneron Pharmaceuticals Q3 Earnings Preview Benzinga
08:39AM  Why Regeneron (REGN) Might Surprise This Earnings Season Zacks
08:00AM  Three Steps That Help Make This One Of The Best Mutual Funds Investor's Business Daily
07:55AM  5 Drug/Biotech Stocks Set to Trump Estimates in Q3 Earnings Zacks
Nov-02-18 10:17AM  bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat Zacks
Nov-01-18 06:50PM  Regeneron (REGN) to Report Q3 Earnings: Is a Beat in Store? Zacks
10:57AM  Is a Disappointment in Store for bluebird (BLUE) Q3 Earnings? Zacks
07:42AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Amgen, Vertex Pharmaceuticals, Celgene and Regeneron Pharmaceuticals Zacks
Oct-31-18 04:52PM  Sanofi (SNY) Q3 2018 Earnings Conference Call Transcript Motley Fool
02:27PM  Esperion CEO on safety of new cholesterol drug CNBC Videos
02:08PM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal Zacks
Oct-29-18 03:38PM  Drugmakers tout new medicines as eye disease battle intensifies Reuters
12:09PM  7 Rising Healthcare Stocks to Consider InvestorPlace
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fenimore Christopher R.VP ControllerJan 18Option Exercise21.251503,1887,246Jan 18 05:01 PM
GOLDSTEIN JOSEPH LDirectorJan 10Option Exercise273.671,791490,14314,114Jan 11 04:06 PM
GOLDSTEIN JOSEPH LDirectorJan 10Sale410.001,791734,31012,323Jan 11 04:06 PM
Fenimore Christopher R.VP ControllerDec 20Option Exercise21.2567514,3448,944Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 20Sale358.971,848663,3817,096Dec 20 05:36 PM
Fenimore Christopher R.VP ControllerDec 19Option Exercise52.033,450179,5049,871Dec 20 05:36 PM
YANCOPOULOS GEORGEPresident and Chief ScientificDec 13Option Exercise16.80244,0484,100,006167,185Dec 17 04:02 PM
SCHLEIFER LEONARD SPresident & CEODec 13Option Exercise16.80312,5005,250,000488,014Dec 14 04:19 PM
VAGELOS P ROYChairman of the BoardDec 12Sale382.3262,2942,304Dec 14 04:49 PM
GOLDSTEIN JOSEPH LDirectorSep 28Option Exercise273.67709194,03212,709Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 28Sale410.00709290,69012,000Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 27Option Exercise273.672,000547,34014,000Oct 01 04:06 PM
BROWN MICHAEL SDirectorSep 27Option Exercise273.672,000547,3402,000Sep 28 04:35 PM
BROWN MICHAEL SDirectorSep 27Sale392.262,000784,5240Sep 28 04:35 PM
GOLDSTEIN JOSEPH LDirectorSep 27Sale400.002,000800,00012,000Oct 01 04:06 PM
GOLDSTEIN JOSEPH LDirectorSep 24Option Exercise273.672,000547,34013,000Sep 25 04:05 PM
GOLDSTEIN JOSEPH LDirectorSep 24Sale388.652,000777,29012,000Sep 25 04:05 PM
Fenimore Christopher R.VP ControllerAug 30Option Exercise21.25501,063200Aug 31 04:02 PM
BROWN MICHAEL SDirectorAug 22Option Exercise177.821,500266,7301,500Aug 23 04:01 PM
BROWN MICHAEL SDirectorAug 22Sale380.491,500570,7350Aug 23 04:01 PM
VAGELOS P ROYChairman of the BoardAug 20Option Exercise21.252104,463400,057Aug 21 04:55 PM
GOLDSTEIN JOSEPH LDirectorAug 02Option Exercise57.112,000114,22014,000Aug 03 04:03 PM
GOLDSTEIN JOSEPH LDirectorAug 02Sale380.002,000760,00012,000Aug 03 04:03 PM
VAGELOS P ROYChairman of the BoardJul 10Sale367.2274,67027,420,277399,847Jul 11 04:04 PM
VAGELOS P ROYChairman of the BoardJul 09Option Exercise16.80153,2742,575,003553,121Jul 11 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 06Sale370.002,000740,00012,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Option Exercise57.112,000114,22014,000Jul 09 04:04 PM
GOLDSTEIN JOSEPH LDirectorJul 05Sale360.002,000720,00012,000Jul 09 04:04 PM
VAGELOS P ROYChairman of the BoardJun 21Sale327.8774,71024,495,410399,847Jun 22 04:03 PM
VAGELOS P ROYChairman of the BoardJun 20Option Exercise16.80153,2742,575,003553,121Jun 22 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 24Sale295.0911,4073,366,09231,973May 25 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 23Option Exercise30.6326,736818,92458,709May 25 04:03 PM
SING GEORGE LDirectorMay 10Sale286.6213,0003,726,000114,772May 11 04:02 PM
SING GEORGE LDirectorMay 09Sale285.297,0001,997,030127,772May 11 04:02 PM
GOLDSTEIN JOSEPH LDirectorMar 19Option Exercise57.112,000114,22014,000Mar 19 04:47 PM
GOLDSTEIN JOSEPH LDirectorMar 19Sale350.022,000700,04012,000Mar 19 04:47 PM
GOLDSTEIN JOSEPH LDirectorMar 14Option Exercise57.112,000114,22014,000Mar 14 04:01 PM
GOLDSTEIN JOSEPH LDirectorMar 14Sale340.002,000680,00012,000Mar 14 04:01 PM
GOLDSTEIN JOSEPH LDirectorFeb 09Sale325.601,000325,60012,000Feb 13 04:01 PM